Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of autoimmune disorders and associated conditions, globally
3.2.1.2 Advances in biotechnology and immunology
3.2.1.3 Rising awareness among healthcare professionals and patients
3.2.2 Industry pitfalls & challenges
3.2.2.1 High costs associated with novel therapies and ongoing treatment regimens
3.2.2.2 Regulatory challenges and stringent approval processes for new treatment modalities
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Future market trends
3.6 Regulatory landscape
3.7 Patent analysis
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Warm autoimmune hemolytic anemia
5.3 Cold autoimmune hemolytic anemia
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Corticosteroids
6.3 Immunosuppressive agents
6.4 Other treatment types
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Injectable
7.3 Oral
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 E-commerce
8.5 Other distribution channels
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Amgen Inc.
10.3 AstraZeneca
10.4 Biogen Inc.
10.5 Bristol-Myers Squibb Company
10.6 Baxter International Inc.
10.7 Eli Lilly and Company
10.8 Gilead Sciences, Inc.
10.9 Johnson & Johnson Services, Inc.
10.10 Merck & Co., Inc.
10.11 Novartis AG
10.12 Pfizer Inc.
10.13 F. Hoffmann-La Roche Ltd
10.14 Sanofi
10.15 Takeda Pharmaceutical Company Limited
